Skip to main content
Premium Trial:

Request an Annual Quote

IsoPlexis: Siddhartha Kadia

Siddhartha Kadia has joined the board of directors of single-cell proteomics firm IsoPlexis. Previously, he was president of the life sciences division at Life Technologies; president and CEO of EAG Laboratories; and corporate VP at Invitrogen. He also serves as director of NuVasive, ALS, Applied Technical Services (ATS), and BioSkryb Genomics. Kadia holds a master's degree from Rutgers University and a PhD in biomedical engineering from Johns Hopkins University.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.